Modality
Gene Therapy
MOA
PRMT5i
Target
FXIa
Pathway
Checkpoint
OCDRB
Development Pipeline
Preclinical
~Dec 2014
→ ~Mar 2016
Phase 1
~Jun 2016
→ ~Sep 2017
Phase 2
Dec 2017
→ Jan 2025
Phase 2Current
NCT07558107
689 pts·OCD
2025-01→TBD·Not yet recruiting
NCT06397573
1,514 pts·OCD
2017-12→TBD·Terminated
2,203 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
P2
Termina…
P2
Not yet…
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07558107 | Phase 2 | OCD | Not yet recr... | 689 | LiverFat |
| NCT06397573 | Phase 2 | OCD | Terminated | 1514 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |